REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. AMENDMENT NO. 4 TO LETTER AGREEMENTDevelopment Program Letter Agreement • November 14th, 2023 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment No. 4 (“Amendment No. 4”) to the Development Program Letter Agreement of May 16, 2017, as amended on July 13, 2018, July 30, 2019 and December 21, 2021 (as amended, the “Agreement”), is entered into and effective as of September 25, 2023 (the “Amendment No. 4 Effective Date”) by and between Arcturus Therapeutics, Inc. (“Arcturus”) and the Cystic Fibrosis Foundation (“CFF”). Capitalized terms used but not defined herein have the meanings given to them in the Agreement.
AMENDMENT NO. 2 TO LETTER AGREEMENTDevelopment Program Letter Agreement • August 14th, 2019 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the Development Program Letter Agreement of May 16, 2017 is entered into and effective as of August 1, 2019 (the “Amendment No. 2 Effective Date”) by and between Arcturus Therapeutics, Inc. (“Arcturus”) and the Cystic Fibrosis Foundation (“CFF”).
AMENDMENT NO. 1 TO LETTER AGREEMENTDevelopment Program Letter Agreement • March 28th, 2019 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 ("Amendment No. 1") to the Development Program Letter Agreement is entered into and effective as of November 26, 2018 ("Amendment No. 1 Effective Date") by and between Aridis Pharmaceuticals, Inc. ("Aridis") and Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT").
